David Lagorce
Overview
Explore the profile of David Lagorce including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1576
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gargano M, Matentzoglu N, Coleman B, Addo-Lartey E, Anagnostopoulos A, Anderton J, et al.
Nucleic Acids Res
. 2023 Nov;
52(D1):D1333-D1346.
PMID: 37953324
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses...
2.
Lagorce D, Lebreton E, Matalonga L, Hongnat O, Chahdil M, Piscia D, et al.
Eur J Hum Genet
. 2023 Nov;
32(2):182-189.
PMID: 37926714
Rare diseases (RD) have a prevalence of not more than 1/2000 persons in the European population, and are characterised by the difficulty experienced in obtaining a correct and timely diagnosis....
3.
Kohler S, Gargano M, Matentzoglu N, Carmody L, Lewis-Smith D, Vasilevsky N, et al.
Nucleic Acids Res
. 2020 Dec;
49(D1):D1207-D1217.
PMID: 33264411
The Human Phenotype Ontology (HPO, https://hpo.jax.org) was launched in 2008 to provide a comprehensive logical standard to describe and computationally analyze phenotypic abnormalities found in human disease. The HPO is...
4.
Bosc N, Muller C, Hoffer L, Lagorce D, Bourg S, Derviaux C, et al.
ACS Chem Biol
. 2020 Apr;
15(6):1566-1574.
PMID: 32320205
Protein-protein interactions (PPIs) mediate nearly every cellular process and represent attractive targets for modulating disease states but are challenging to target with small molecules. Despite this, several PPI inhibitors (iPPIs)...
5.
Lagorce D, Bouslama L, Becot J, Miteva M, Villoutreix B
Bioinformatics
. 2017 Sep;
33(22):3658-3660.
PMID: 28961788
Motivation: Identification of small molecules that could be interesting starting points for drug discovery or to investigate a biological system as in chemical biology endeavours is both time consuming and...
6.
Louet M, Bitam S, Bakouh N, Bignon Y, Planelles G, Lagorce D, et al.
Sci Rep
. 2017 Aug;
7(1):7249.
PMID: 28775266
The human ClC-Kb channel plays a key role in exporting chloride ions from the cytosol and is known to be involved in Bartter syndrome type 3 when its permeation capacity...
7.
Lagorce D, Oliveira N, Miteva M, Villoutreix B
Drug Discov Today
. 2017 Jul;
22(8):1131-1133.
PMID: 28676405
No abstract available.
8.
Lagorce D, Douguet D, Miteva M, Villoutreix B
Sci Rep
. 2017 Apr;
7:46277.
PMID: 28397808
The modulation of PPIs by low molecular weight chemical compounds, particularly by orally bioavailable molecules, would be very valuable in numerous disease indications. However, it is known that PPI inhibitors...
9.
Labbe C, Kuenemann M, Zarzycka B, Vriend G, Nicolaes G, Lagorce D, et al.
Nucleic Acids Res
. 2015 Oct;
44(D1):D542-7.
PMID: 26432833
In order to boost the identification of low-molecular-weight drugs on protein-protein interactions (PPI), it is essential to properly collect and annotate experimental data about successful examples. This provides the scientific...
10.
Lagorce D, Sperandio O, Baell J, Miteva M, Villoutreix B
Nucleic Acids Res
. 2015 Apr;
43(W1):W200-7.
PMID: 25883137
Drug attrition late in preclinical or clinical development is a serious economic problem in the field of drug discovery. These problems can be linked, in part, to the quality of...